The FDA Said No. Europe Said Yes. Someone Is Wrong About Camizestrant.

Pull up the FDA advisory committee transcript from last month and read the vote. The panel reviewing AstraZeneca’s camizestrant — branded Etcamah in Europe — recommended against approval, citing concerns about the evidence package for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Then open the EMA’s CHMP opinion page, published less than thirty days later: positive opinion, marketing authorization recommended, indication confirmed. Same drug. Same dossier. Opposite conclusions. What does it say about global regulatory alignment — and about AstraZeneca‘s dossier strategy — when the two most influential drug-approval bodies on the planet can look at identical efficacy data and arrive at diametrically opposed verdicts?

That question deserves more than a shrug from the oncology community. Regulatory divergence is not a curiosity — it is an operational signal. Either the FDA advisory panel overreached, or the CHMP accepted evidence that should have triggered the same skepticism. One of those institutions is currently wrong about whether camizestrant belongs in the hands of patients with ESR1-mutated breast cancer, and sponsors, sites, and patients deserve to know which one.

The Dossier That Split Two Continents

The CHMP’s positive opinion for Etcamah is specific: ER-positive, HER2-negative, locally advanced or metastatic breast cancer in adult patients carrying ESR1 gene mutations, used without prior disease progression. That is a narrow, biomarker-gated indication — precisely the kind of precision oncology carve-out that tends to sail through European review because the committee is willing to accept a survival benefit in a defined molecular subgroup even when overall survival data remain immature. The FDA’s advisory committee, applying its own evidentiary framework, apparently concluded that the benefit-risk calculus did not clear the bar.

AstraZeneca has not disclosed the precise vote tally from the FDA panel in public communications reviewed for this column, but the FiercePharma report confirms the advisory committee recommended rejection. The gap between that vote and the CHMP’s thumbs-up — achieved within the same calendar month — exposes something the press release cycle obscures: AstraZeneca built a single regulatory dossier and bet that it would land on both sides of the Atlantic simultaneously. That bet lost in Washington and won in Amsterdam, and the company now faces the uncomfortable task of explaining why a drug approved for European patients remains unapproved in the United States.

The structural asymmetry here matters operationally. The CHMP and FDA do not share evidentiary thresholds, particularly in oncology. A J Cancer Policy analysis published May 2026 covering regulatory approvals from 2020 through 2024 found the FDA granted 73 first-time oncology drug approvals during that window — a figure that reflects a demanding standard applied across multiple indication types. Divergence between the two agencies in oncology is not rare, but when it occurs within weeks on the same application, it signals that one agency caught something the other weighted differently. The question for AstraZeneca’s regulatory affairs team is whether they knew the FDA panel would fracture on the evidence and submitted anyway, or whether they genuinely expected alignment.

The Endpoint Problem No One Is Naming

The FDA’s suspicion almost certainly traces to endpoint maturity. The CHMP indication language — “without disease progression during first-line treatment” — implies the pivotal data package rests heavily on progression-free survival in a first-line or maintenance context. PFS is a surrogate. In metastatic breast cancer, regulatory agencies have historically accepted PFS as a primary endpoint, but the FDA has grown demonstrably more cautious about surrogate-only packages in the accelerated approval era, particularly after the oncology cohort withdrawals that followed the 2021–2022 confirmatory-trial cleanup.

If the camizestrant pivotal trial — AstraZeneca has been running the SERENA-6 study in ESR1-mutated ER-positive breast cancer — produced a robust PFS signal without mature overall survival data, the FDA panel’s hesitation follows a recognizable pattern. The committee has seen this film before: a precision oncology drug with a compelling biomarker hypothesis, a statistically significant PFS readout, and an OS curve that hasn’t had time to separate. The CHMP, operating under a framework that more readily grants conditional marketing authorizations pending post-authorization efficacy studies, may have accepted that tradeoff explicitly. The FDA panel may have refused it implicitly.

That creates a direct operational problem for AstraZeneca. A conditional EMA approval requires post-authorization confirmatory data — meaning AstraZeneca will need to run or complete a trial that produces the OS evidence the FDA panel may have been asking for in the first place. If the company is now committed to generating that data for European regulators, the FDA’s rejection looks less like an overreach and more like a preview of the confirmatory burden AZ was going to face regardless. Running toward European approval while the US door stays closed is not a regulatory win — it is a timeline that extends the commercial gap by years.

The Aduhelm precedent is worth invoking here, not as a parallel but as a contrast. When the FDA approved Biogen’s aducanumab in 2021 despite its advisory committee’s negative vote, the agency absorbed years of institutional damage. The lesson was not lost: FDA panels now carry more visible weight in the post-accelerated-approval-reform environment. Overturning a negative adcom recommendation requires the agency to put its reasoning in writing and defend it publicly. The inverse — following the panel’s rejection — requires no such defense. Which means AstraZeneca cannot count on the FDA simply ignoring its advisory committee and approving Etcamah on its own motion. If the company wants US approval, it will need to answer the panel’s specific objections with new or reanalyzed data.

What AstraZeneca Owes the US Patient

For sponsors watching this play out, the operational lesson is blunt: do not treat a global regulatory submission as a single dossier that will be evaluated identically by agencies operating under different evidentiary frameworks. AstraZeneca’s situation is not unique — the J Cancer Policy dataset shows divergence across dozens of oncology applications between 2020 and 2024 — but the speed of the split, with a US rejection and a European positive opinion in the same thirty-day window, is an unusually public demonstration of what happens when a company bets on convergence and loses.

For sites enrolling ESR1-mutation-screened breast cancer patients in AstraZeneca-sponsored trials, the immediate question is whether camizestrant’s US development program continues under the current protocol or whether AstraZeneca regroups around a new endpoint strategy. The FDA’s adcom rejection does not constitute a Complete Response Letter — the formal CRL, if it comes, will specify what the agency needs. Site investigators and IRBs should watch that CRL language closely. If the FDA asks for mature OS data from SERENA-6 or a new confirmatory study, the enrollment implications run into years, not months, and patient eligibility windows in metastatic breast cancer are not infinitely patient.

For FDA-watchers, the forward signal is the agency’s formal action date on camizestrant following the advisory committee’s recommendation. The PDUFA date, whenever it falls, will test whether the FDA follows its panel or diverges — and under the current post-Aduhelm institutional memory, divergence remains the harder path. Meanwhile, the CHMP’s positive opinion will convert to a European Commission marketing authorization on its standard timeline, meaning Etcamah will be commercially available to European oncologists while US patients and their physicians wait for a resolution that may require an entirely new data package to achieve.

Watch for AstraZeneca’s response to the FDA in the next sixty days. That document — whatever form it takes — will reveal whether the company believes it can defend the existing evidence or whether it concedes the panel’s concerns and commits to generating the OS data that should have been the foundation of both submissions from the start.

References

1. FiercePharma — “Europe’s CHMP gives thumbs up to AZ’s breast cancer drug after thumbs down from FDA adcomm”
2. European Medicines Agency — Etcamah (camizestrant) EPAR and CHMP Opinion
3. J Cancer Policy — “Regulatory approval of new oncology drugs, 2020-2024: A comparative analysis of FDA, EMA, and ANVISA” (May 2026)
4. Pink Sheet via 3D Communications — “Advisory Committee Disagreement with US FDA on Approval Decisions: An Increasingly Rare Event”